Zevra Therapeutics, Inc. Operating Income
Zevra Therapeutics, Inc. (ZVRA) reported Operating Income of $16.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Zevra Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was $16.78M.
- Zevra Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was $52.15M.
- Zevra Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was $9.31M.
- Zevra Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was $4.14M.
- Zevra Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$62.94M.
- Zevra Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$87.00M.
- Zevra Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$49.60M.
- Zevra Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$42.56M, a 650.72% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.78M 10-Q · filed 2026-08-05 | $68.92M 10-Q · filed 2026-08-05 | $78.24M derived: sum of 3 quarters · filed 2026-08-05 | $82.38M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $52.15M 10-Q · filed 2026-05-06 | $61.46M derived: sum of 2 quarters · filed 2026-05-06 | $65.60M derived: sum of 3 quarters · filed 2026-05-06 | -$5.43M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $13.46M derived: sum of 2 quarters · filed 2026-03-09 | -$57.58M derived: sum of 3 quarters · filed 2026-08-05 | -$62.94M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $4.14M 10-Q · filed 2025-11-05 | -$66.90M derived: sum of 2 quarters · filed 2026-08-05 | -$72.26M 10-Q · filed 2025-11-05 | -$87.67M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$71.04M 10-Q · filed 2026-08-05 | -$76.40M 10-Q · filed 2026-08-05 | -$91.82M derived: sum of 3 quarters · filed 2026-08-05 | -$119.12M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$5.36M 10-Q · filed 2026-05-06 | -$20.78M derived: sum of 2 quarters · filed 2026-05-06 | -$48.08M derived: sum of 3 quarters · filed 2026-05-06 | -$71.88M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$15.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$42.72M derived: sum of 2 quarters · filed 2026-03-09 | -$66.52M derived: sum of 3 quarters · filed 2026-03-09 | -$87.00M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$27.31M 10-Q · filed 2025-11-05 | -$51.10M derived: sum of 2 quarters · filed 2025-11-05 | -$71.59M 10-Q · filed 2025-11-05 | -$86.74M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$23.80M 10-Q · filed 2025-08-12 | -$44.28M 10-Q · filed 2025-08-12 | -$59.44M derived: sum of 3 quarters · filed 2025-08-12 | -$74.80M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$20.49M 10-Q · filed 2025-05-13 | -$35.64M derived: sum of 2 quarters · filed 2025-05-13 | -$51.01M derived: sum of 3 quarters · filed 2025-05-13 | -$57.26M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$30.52M derived: sum of 2 quarters · filed 2025-03-12 | -$36.77M derived: sum of 3 quarters · filed 2025-03-12 | -$49.60M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | -$15.36M 10-Q · filed 2024-11-13 | -$21.62M derived: sum of 2 quarters · filed 2024-11-13 | -$34.45M 10-Q · filed 2024-11-13 | -$34.93M 10-Q · filed 2023-11-07 | -$43.76M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$6.25M 10-Q · filed 2024-08-14 | -$6.64M 10-Q · filed 2023-08-14 | -$19.08M 10-Q · filed 2024-08-14 | -$19.57M 10-Q · filed 2023-08-14 | -$28.40M derived: sum of 3 quarters · filed 2024-08-14 | -$35.02M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$12.83M 10-Q · filed 2024-05-09 | -$12.92M 10-Q · filed 2023-05-15 | -$22.14M derived: sum of 2 quarters · filed 2024-05-09 | -$28.77M derived: sum of 3 quarters · filed 2024-05-09 | -$53.54M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$15.94M derived: sum of 2 quarters · filed 2024-04-01 | -$40.71M derived: sum of 3 quarters · filed 2024-04-01 | -$42.56M 10-K · filed 2024-04-01 | -$42.51M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | -$6.63M 10-Q · filed 2023-11-07 | -$31.39M derived: sum of 2 quarters · filed 2023-11-07 | -$33.25M 10-Q · filed 2023-11-07 | -$36.09M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$24.77M 10-Q · filed 2023-08-14 | -$26.63M 10-Q · filed 2023-08-14 | -$29.47M derived: sum of 3 quarters · filed 2023-08-14 | -$31.69M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$1.86M 10-Q · filed 2023-05-15 | -$4.70M derived: sum of 2 quarters · filed 2023-05-15 | -$6.92M derived: sum of 3 quarters · filed 2023-05-15 | -$1.09M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$5.06M derived: sum of 2 quarters · filed 2023-03-07 | $769.00K derived: sum of 3 quarters · filed 2023-03-07 | $7.73M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | -$2.22M 10-Q · filed 2022-11-10 | $3.61M derived: sum of 2 quarters · filed 2022-11-10 | $10.57M 10-Q · filed 2022-11-10 | $7.36M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $5.83M 10-Q · filed 2022-08-12 | $12.79M 10-Q · filed 2022-08-12 | $9.58M derived: sum of 3 quarters · filed 2022-08-12 | $8.37M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $6.96M 10-Q · filed 2022-05-12 | $3.75M derived: sum of 2 quarters · filed 2022-05-12 | $2.53M derived: sum of 3 quarters · filed 2022-05-12 | $5.13M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$4.43M derived: sum of 2 quarters · filed 2022-03-31 | -$1.83M derived: sum of 3 quarters · filed 2022-03-31 | -$5.61M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$1.21M 10-Q · filed 2021-11-10 | $1.38M derived: sum of 2 quarters · filed 2021-11-10 | -$2.40M 10-Q · filed 2021-11-10 | -$6.80M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $2.59M 10-Q · filed 2021-08-13 | -$1.18M 10-Q · filed 2021-08-13 | -$5.59M derived: sum of 3 quarters · filed 2021-08-13 | -$2.36M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$3.77M 10-Q · filed 2021-05-14 | -$8.19M derived: sum of 2 quarters · filed 2021-05-14 | -$4.95M derived: sum of 3 quarters · filed 2021-05-14 | -$12.74M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | -$4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$1.18M derived: sum of 2 quarters · filed 2021-03-12 | -$8.97M derived: sum of 3 quarters · filed 2021-03-12 | -$20.34M 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | $3.23M 10-Q · filed 2020-10-30 | -$4.56M derived: sum of 2 quarters · filed 2020-10-30 | -$15.93M 10-Q · filed 2020-10-30 | -$25.20M derived: sum of 4 quarters · filed 2020-10-30 | ||||
| 2019-06-30 | -$7.79M 10-Q · filed 2020-08-12 | -$19.16M 10-Q · filed 2020-08-12 | -$28.43M derived: sum of 3 quarters · filed 2020-08-12 | -$46.39M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | -$11.37M 10-Q · filed 2020-05-13 | -$20.64M derived: sum of 2 quarters · filed 2020-05-13 | -$38.59M derived: sum of 3 quarters · filed 2020-05-13 | -$52.50M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | -$9.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$27.23M derived: sum of 2 quarters · filed 2020-02-28 | -$41.13M derived: sum of 3 quarters · filed 2020-02-28 | -$55.90M 10-K · filed 2020-02-28 | ||||
| 2018-09-30 | -$17.96M 10-Q · filed 2019-11-14 | -$31.87M derived: sum of 2 quarters · filed 2019-11-14 | -$46.63M 10-Q · filed 2019-11-14 | -$54.78M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | -$13.91M 10-Q · filed 2019-08-13 | -$28.68M 10-Q · filed 2019-08-13 | -$36.83M derived: sum of 3 quarters · filed 2019-08-13 | -$46.44M derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-03-31 | -$14.77M 10-Q · filed 2019-05-14 | -$22.92M derived: sum of 2 quarters · filed 2019-05-14 | -$32.53M derived: sum of 3 quarters · filed 2019-05-14 | -$40.76M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | -$8.15M 10-K · filed 2018-03-30 | -$17.76M derived: sum of 2 quarters · filed 2018-11-09 | -$25.99M derived: sum of 3 quarters · filed 2018-11-09 | -$33.37M 10-K · filed 2019-03-01 | ||||
| 2017-09-30 | -$9.61M 10-Q · filed 2018-11-09 | -$17.84M derived: sum of 2 quarters · filed 2018-11-09 | -$25.22M 10-Q · filed 2018-11-09 | -$36.05M derived: sum of 4 quarters · filed 2018-11-09 | ||||
| 2017-06-30 | -$8.22M 10-Q · filed 2018-08-10 | -$15.60M 10-Q · filed 2018-08-10 | -$26.44M derived: sum of 3 quarters · filed 2018-08-10 | -$36.84M derived: sum of 4 quarters · filed 2018-08-10 | ||||
| 2017-03-31 | -$7.38M 10-Q · filed 2018-05-11 | -$18.22M derived: sum of 2 quarters · filed 2018-05-11 | -$28.62M derived: sum of 3 quarters · filed 2018-05-11 | -$37.89M derived: sum of 4 quarters · filed 2018-05-11 | ||||
| 2016-12-31 | -$10.84M 10-K · filed 2018-03-30 | -$21.24M derived: sum of 2 quarters · filed 2018-03-30 | -$30.51M derived: sum of 3 quarters · filed 2018-03-30 | -$37.48M 10-K · filed 2018-03-30 | ||||
| 2016-09-30 | -$10.40M 10-K · filed 2018-03-30 | -$19.68M derived: sum of 2 quarters · filed 2018-03-30 | -$26.65M 10-Q · filed 2017-11-09 | -$33.93M derived: sum of 4 quarters · filed 2018-03-30 | ||||
| 2016-06-30 | -$9.28M 10-K · filed 2018-03-30 | -$16.25M 10-Q · filed 2017-08-10 | -$23.53M derived: sum of 3 quarters · filed 2018-03-30 | -$30.01M derived: sum of 4 quarters · filed 2018-03-30 | ||||
| 2016-03-31 | -$6.97M 10-K · filed 2018-03-30 | -$14.25M derived: sum of 2 quarters · filed 2018-03-30 | -$20.73M derived: sum of 3 quarters · filed 2018-03-30 | -$26.69M derived: sum of 4 quarters · filed 2018-03-30 | ||||
| 2015-12-31 | -$7.28M 10-K · filed 2017-03-10 | -$13.76M derived: sum of 2 quarters · filed 2017-03-10 | -$19.72M derived: sum of 3 quarters · filed 2017-03-10 | -$22.81M 10-K · filed 2018-03-30 | ||||
| 2015-09-30 | -$6.48M 10-K · filed 2017-03-10 | -$12.44M derived: sum of 2 quarters · filed 2017-03-10 | -$15.53M 10-Q · filed 2016-11-10 | -$23.02M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2015-06-30 | -$5.96M 10-K · filed 2017-03-10 | -$9.05M 10-Q · filed 2016-08-11 | -$16.54M derived: sum of 3 quarters · filed 2017-03-10 | -$20.88M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2015-03-31 | -$3.10M 10-K · filed 2017-03-10 | -$10.58M derived: sum of 2 quarters · filed 2017-03-10 | -$14.92M derived: sum of 3 quarters · filed 2017-03-10 | -$17.97M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2014-12-31 | -$7.49M 10-K · filed 2016-03-16 | -$11.83M derived: sum of 2 quarters · filed 2016-03-16 | -$14.87M derived: sum of 3 quarters · filed 2016-03-16 | -$16.44M 10-K · filed 2017-03-10 | ||||
| 2014-09-30 | -$4.34M 10-K · filed 2016-03-16 | -$7.38M derived: sum of 2 quarters · filed 2016-03-16 | -$8.96M 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | -$3.04M 10-K · filed 2016-03-16 | -$4.62M 10-Q · filed 2015-08-14 | ||||||
| 2014-03-31 | -$1.57M 10-K · filed 2016-03-16 | |||||||
| 2013-12-31 | -$4.72M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |